Yuflyma (adalimumab-aaty) vs Tofidence (tocilizumab-bavi)
Yuflyma (adalimumab-aaty) vs Tofidence (tocilizumab-bavi)
Yuflyma (adalimumab-aaty) is a biosimilar to the original adalimumab and is a tumor necrosis factor (TNF) inhibitor used to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. Tofidence (tocilizumab-bavi), on the other hand, is a biosimilar to tocilizumab and works differently by blocking the interleukin-6 (IL-6) receptor, which also makes it effective for rheumatoid arthritis and other inflammatory conditions. When deciding between the two, it's important to consider the specific condition being treated, the patient's medical history, and how their body has responded to similar treatments, as each medication has a distinct mechanism of action and potential side effect profile.
Difference between Yuflyma and Tofidence
| Metric | Yuflyma (adalimumab-aaty) | Tofidence (tocilizumab-bavi) |
|---|---|---|
| Generic name | Adalimumab-aaty | Tocilizumab-bavi |
| Indications | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis | Rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis, cytokine release syndrome |
| Mechanism of action | TNF inhibitor | IL-6 receptor antagonist |
| Brand names | Yuflyma | Tofidence |
| Administrative route | Subcutaneous injection | Intravenous infusion, subcutaneous injection |
| Side effects | Infections, injection site reactions, headache, rash | Upper respiratory tract infections, headache, hypertension, increased liver enzymes |
| Contraindications | Active tuberculosis, serious infections, hypersensitivity to adalimumab or its excipients | Active, serious infections, hypersensitivity to tocilizumab or its excipients |
| Drug class | Monoclonal antibody, TNF inhibitor | Monoclonal antibody, IL-6 inhibitor |
| Manufacturer | Celltrion Healthcare Co., Ltd. | Polpharma Biologics S.A. |
Efficacy
Introduction to Yuflyma (adalimumab-aaty)
Yuflyma (adalimumab-aaty) is a biosimilar to the reference product Humira, which is a well-established treatment for rheumatoid arthritis (RA). As a tumor necrosis factor (TNF) blocker, Yuflyma has been developed to match the efficacy and safety profile of its reference product. In clinical trials, Yuflyma has demonstrated its ability to reduce the signs and symptoms of RA, inhibit the progression of structural damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis.
Efficacy of Yuflyma in Rheumatoid Arthritis
The efficacy of Yuflyma for the treatment of rheumatoid arthritis is supported by pharmacokinetic and pharmacodynamic studies, which confirm its similarity to the reference product. Clinical studies have shown that patients treated with Yuflyma experience significant improvements in RA symptoms, including joint pain, swelling, and stiffness. Additionally, Yuflyma has been shown to slow the progression of joint damage in RA patients, which is a critical aspect of managing the disease long-term.
Introduction to Tofidence (tocilizumab-bavi)
Tofidence (tocilizumab-bavi) is a biosimilar to the reference product Actemra and is an interleukin-6 (IL-6) receptor antagonist. It has been developed for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Tofidence is designed to block the action of IL-6, a cytokine that plays a key role in the inflammatory process of RA, thereby reducing inflammation and slowing disease progression.
Efficacy of Tofidence in Rheumatoid Arthritis
Clinical trials have demonstrated that Tofidence is effective in reducing the signs and symptoms of rheumatoid arthritis. Patients receiving Tofidence have shown improvement in both physical function and quality of life. The efficacy of Tofidence in reducing disease activity is comparable to that of the reference product, with similar rates of clinical remission and low disease activity being reported. Furthermore, Tofidence has been shown to inhibit the progression of joint damage, which is paramount in preserving joint integrity and function in RA patients.
Regulatory Agency Approvals
Yuflyma
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Tofidence
-
Food and Drug Administration (FDA), USA
Access Yuflyma or Tofidence today
If Yuflyma or Tofidence are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us